Screener
Vaxcyte, Inc. PCVX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 1,813,488 | 1,627,361 |
| Property and equipment, net | 260,695 | 257,370 |
| Operating lease right-of-use assets | 113,103 | 116,009 |
| Long-term investments | 1,004,017 | 881,664 |
| Restricted cash | 1,466 | 1,466 |
| Other assets | 155,539 | 118,847 |
| Total noncurrent assets | 1,534,820 | 1,375,356 |
| Total assets | $3,348,308 | $3,002,717 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s equity method investments?
- Vaxcyte, Inc. (PCVX) reported equity method investments of $1B in Q1 2026.
- How has Vaxcyte, Inc.'s equity method investments changed year-over-year?
- Vaxcyte, Inc.'s equity method investments decreased by 21.5% year-over-year, from $1.28B to $1B.
- What is the long-term trend for Vaxcyte, Inc.'s equity method investments?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s equity method investments has grown at a 138.8% compound annual growth rate (CAGR), from $27.12M to $881.66M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Vaxcyte, Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude